
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Neurol.
Sec. Pediatric Neurology
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1541507
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: SMA Type 1 is the most severe form of spinal muscular atrophy with early symptom onset, limited motor development, and poor prognosis. Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to four years.: This prospective, non-interventional study included 310 patients with genetically confirmed spinal muscular atrophy at 24 pediatric neurology centers in Turkey. Patients treated with nusinersen were divided into five age-based cohorts at treatment initiation: Cohort A (0-3 months), Cohort B (4-6 months), Cohort C (7-12 months), Cohort D (13-24 months), and Cohort E (>24 months). Efficacy was assessed using the CHOP-INTEND and WHO MotorMilestone Scale. This study also analyzed the respiratory support needs, gastrostomy requirements, and mortality rates across cohorts.Results: Patients treated before 12 months of age showed the most significant improvements in motor milestones, with 58.7% of Cohort A achieving independent sitting. CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). Ventilator and gastrostomy requirements decreased in the early treated cohorts.Adverse events were rare, with one discontinuation due to hydrocephalus. The overall mortality rate was 21.3%, with most of the deaths occurring within the first year.Interpretation: Nusinersen treatment initiated before 12 months of age, especially before 3 months of age, yielded the most favorable motor outcomes in patients with SMA type 1. Early initiation is associated with improved motor milestones and reduced need for ventilatory support. However, no significant improvements were observed in the bulbar function or in patients requiring extensive respiratory support.
Keywords: spinal muscular atrophy, SMA type 1, Motor function, Severe symptomatic, Nusinersen, Ventilatory, bulbar function, Presymptomatic
Received: 07 Dec 2024; Accepted: 19 Feb 2025.
Copyright: © 2025 Bektaş, Gülşen, Dursun, Tekin, Yüksel, Demir, Öztürk, Saltık, Hergüler, Özçelik, Tan, Özgör, Ekici, Feyza, Şahin, Duman, Kömür, Baydan, Pembegül Yıldız, Kara, Yiş, Kanmaz, Bora Çarman, Arslan, Canpolat, Güven, Öztuncer, Ünalp, Ardıçlı, Karaduman, Zararsız, Süt, Ünver, Dilek, Yıldırım, İncecik, Karadağ, Bütün, Gönüllü Polat, Güzin, Kılıç, Deniz, Uzun, Yılmaz, Özdemir, Yarar, Yıldız, Acer, Çaksen, Aydın, Karaoğlu, Çıtak, Kendirli, Tur, Akyüz, Amirov, Gül Mert, Aslan, Haspolat, Ersoy, Kipoğlu, Alikılıç, Tekgul, Kaya, Yücel Sen, Kart, Per, Aksoy, Yılmaz, TEBER, Göktaş, Türkdoğan, Uluğ, Bilge, Coskun, Oztürk, Atmaca, Cansu, Gümüş, KARADAG-SAYGI, Karaca, Gungor, Cobanoglu, Sezgin, Yıldırım, Gökdemir, Şengenç, Zindar, Ozlem, Güngör, Kırık, Direk and Deda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ömer Bektaş, Ankara University, Ankara, Türkiye
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.